Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
Key facts
- Who runs it
- Australian and New Zealand Intensive Care Research Centre
- Where
- Australia, Ireland, and New Zealand50 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 1,000 people enrolled
- Started
- 26 Oct 2021
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vasopressor
- Fluids
- Record updated
- 9 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Clinically suspected infection
- Systolic blood pressure (SBP) <90 mm Hg or mean arterial pressure (MAP) <65 mm Hg, despite a ⩾1000ml cumulative total bolus of IV fluid administered over a maximum of 60 minutes; including pre-hospital boluses
- Arterial or venous blood lactate >2.0 mmol/L
- At least one dose of an intravenous antimicrobial has been commenced
Who cannot take part
- >2L total IV fluid administered (including prehospital fluids but excluding drugs and flushes)
- Treating clinician considers that one or both of the treatment regimens are not suitable for the patient or the study protocol cannot be delivered e.g. limitation of care, requirement for immediate surgery
- Previously enrolled in this study
- Underlying disease that makes survival to 90 days unlikely
- Age <18 years
- Confirmed or suspected pregnancy
- Transferred from another acute care facility
- Hypotension suspected to be due to a non-sepsis cause
- More than 6 hours has elapsed since presentation to the ED or more than 2 hours has elapsed since last inclusion criterion has been met
- Death is considered imminent or inevitable
- Inability to follow patient up to day-90 e.g. unstable accommodation, overseas visitor
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This multicentre, randomised controlled trial will enrol 1000 patients presenting with septic shock to the emergency department (ED) of participating hospitals in Australia and New Zealand. Participants will receive haemodynamic resuscitation with either a restricted fluids and early vasopressor regimen or a larger initial IV fluid volume with later introduction of vasopressors if required. Clinical care including the type of resuscitation fluid and vasopressor agent, will otherwise be in accordance with accepted standard care and according to clinician discretion. The study intervention will be delivered for at least 6 hours and up to 24 hours post-randomisation. Participants will be followed for up to 12 months and outcomes analysed on an intention-to-treat basis.
The 2 groups in the trial
- VasopressorExisting treatment, for comparison
a restricted fluids and early vasopressor strategy
- FluidsExisting treatment, for comparison
a larger intravenous (IV) fluid volume and later vasopressor strategy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Vasopressors or Fluids in Early Septic Shock.The New England journal of medicine, 2026
- Australasian Resuscitation In Sepsis Evaluation: FLUid or vasopressors In emergency Department Sepsis (ARISE FLUIDS) trial: study protocol.BMJ open, 2025
- Record updated
- 9 November 2026